COLUMBIA, Maryland – The outcomes of a recent continuing medical education (CME) program, the results of which were published in the June 20th issue of Evidence-based Oncology in article titled Addressing Oncologists’ Gaps in the Use of Biosimilar Products, demonstrated that prior to the participating in the education activity, only 22% of oncology healthcare providers […]
Category Archives: BioSimilar
04
Mar
Mar
There is a ballooning interest in biosimilars and interchangeable products in the pharmaceutical industry, especially with the first biosimilar in the United States being approved in 2015. The Food and Drug Administration continues to review other marketing applications for proposed biosimilar products. The FDA has announced that they have developed a free, Continuing Education […]
01
Jul
Jul
The North American for Continuing Medical Education, LLC (NACCME) recently announced the results of a survey of oncologists, rheumatologists, managed care professionals, pharmacists, and primary care learners. The study, conducted in April 2013, focused on awareness of and need for information on biosimilar agents, with results strongly supporting the need for comprehensive education on this […]